ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000C56

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial

Identifieur interne : 000C56 ( PascalFrancis/Corpus ); précédent : 000C55; suivant : 000C57

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial

Auteurs : Erich Mohr ; Tilak Mendis ; Kathleen Hildebrand ; Peter Paul De Deyn

Source :

Movement disorders [ 0885-3185 ] ; 2000.

RBID : Pascal:01-0017681

Descripteurs français

Pascal (Inist)
- Parkinson maladie, Psychose, Lévodopa, Chimiothérapie, Antiparkinsonien, Rispéridone, Neuroleptique, Psychotrope, Antagoniste dopamine, Antagoniste sérotonine, Récepteur dopaminergique, Récepteur sérotoninergique, Traitement, Toxicité, Homme, Court terme.

English descriptors

KwdEn :
- Antiparkinson agent, Chemotherapy, Dopamine antagonist, Dopamine receptor, Human, Levodopa, Neuroleptic, Parkinson disease, Psychosis, Psychotropic, Risperidone, Serotonin antagonist, Serotonine receptor, Short term, Toxicity, Treatment.

Abstract

PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (-3.1 decrease) after 1 week and a 66% improvement (-6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)-severity and CGI-improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short-term use of risperidone (mean dosage, 1, 1 mg per day) improves the psychopathology of patients with PD who have dopamine-induced psychosis without adversely affecting the symptoms of PD. Higher doses and long-term use were not addressed in this study and may be precluded by extrapyramidal side effects.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 15`
A06				`@2 6`
A08	`01`	`1`	`ENG`	`@1 Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial`
A11	`01`	`1`		`@1 MOHR (Erich)`
A11	`02`	`1`		`@1 MENDIS (Tilak)`
A11	`03`	`1`		`@1 HILDEBRAND (Kathleen)`
A11	`04`	`1`		`@1 DE DEYN (Peter Paul)`
A14	`01`			`@1 CroMedica Global Inc. @2 Victoria @3 CAN @Z 1 aut. @Z 3 aut.`
A14	`02`			`@1 University of Ottawa @3 CAN @Z 1 aut. @Z 3 aut.`
A14	`03`			`@1 Ottawa Civic Hospital and University of Ottawa @3 CAN @Z 2 aut.`
A14	`04`			`@1 Middelheim Hospital, University of Antwerp @2 Antwerp @3 BEL @Z 4 aut.`
A20				`@1 1230-1237`
A21				`@1 2000`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000092814950260`
A44				`@0 0000 @1 © 2001 INIST-CNRS. All rights reserved.`
A45				`@0 50 ref.`
A47	`01`	`1`		`@0 01-0017681`
A60				`@1 P @3 CC`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (-3.1 decrease) after 1 week and a 66% improvement (-6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)-severity and CGI-improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short-term use of risperidone (mean dosage, 1, 1 mg per day) improves the psychopathology of patients with PD who have dopamine-induced psychosis without adversely affecting the symptoms of PD. Higher doses and long-term use were not addressed in this study and may be precluded by extrapyramidal side effects.
C02	`01`	`X`		`@0 002B02U01`
C03	`01`	`X`	`FRE`	`@0 Parkinson maladie @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @5 01`
C03	`02`	`X`	`FRE`	`@0 Psychose @5 04`
C03	`02`	`X`	`ENG`	`@0 Psychosis @5 04`
C03	`02`	`X`	`SPA`	`@0 Psicosis @5 04`
C03	`03`	`X`	`FRE`	`@0 Lévodopa @5 07`
C03	`03`	`X`	`ENG`	`@0 Levodopa @5 07`
C03	`03`	`X`	`SPA`	`@0 Levodopa @5 07`
C03	`04`	`X`	`FRE`	`@0 Chimiothérapie @5 08`
C03	`04`	`X`	`ENG`	`@0 Chemotherapy @5 08`
C03	`04`	`X`	`SPA`	`@0 Quimioterapia @5 08`
C03	`05`	`X`	`FRE`	`@0 Antiparkinsonien @5 09`
C03	`05`	`X`	`ENG`	`@0 Antiparkinson agent @5 09`
C03	`05`	`X`	`SPA`	`@0 Antiparkinsoniano @5 09`
C03	`06`	`X`	`FRE`	`@0 Rispéridone @2 NK @2 FR @5 10`
C03	`06`	`X`	`ENG`	`@0 Risperidone @2 NK @2 FR @5 10`
C03	`06`	`X`	`SPA`	`@0 Risperidona @2 NK @2 FR @5 10`
C03	`07`	`X`	`FRE`	`@0 Neuroleptique @5 11`
C03	`07`	`X`	`ENG`	`@0 Neuroleptic @5 11`
C03	`07`	`X`	`SPA`	`@0 Neuroléptico @5 11`
C03	`08`	`X`	`FRE`	`@0 Psychotrope @2 FX @5 12`
C03	`08`	`X`	`ENG`	`@0 Psychotropic @2 FX @5 12`
C03	`08`	`X`	`SPA`	`@0 Psicotropo @2 FX @5 12`
C03	`09`	`X`	`FRE`	`@0 Antagoniste dopamine @5 13`
C03	`09`	`X`	`ENG`	`@0 Dopamine antagonist @5 13`
C03	`09`	`X`	`SPA`	`@0 Antagonista dopamina @5 13`
C03	`10`	`X`	`FRE`	`@0 Antagoniste sérotonine @5 14`
C03	`10`	`X`	`ENG`	`@0 Serotonin antagonist @5 14`
C03	`10`	`X`	`SPA`	`@0 Antagonista serotonina @5 14`
C03	`11`	`X`	`FRE`	`@0 Récepteur dopaminergique @5 15`
C03	`11`	`X`	`ENG`	`@0 Dopamine receptor @5 15`
C03	`11`	`X`	`SPA`	`@0 Receptor dopaminérgico @5 15`
C03	`12`	`X`	`FRE`	`@0 Récepteur sérotoninergique @5 16`
C03	`12`	`X`	`ENG`	`@0 Serotonine receptor @5 16`
C03	`12`	`X`	`SPA`	`@0 Receptor serotoninérgico @5 16`
C03	`13`	`X`	`FRE`	`@0 Traitement @5 17`
C03	`13`	`X`	`ENG`	`@0 Treatment @5 17`
C03	`13`	`X`	`SPA`	`@0 Tratamiento @5 17`
C03	`14`	`X`	`FRE`	`@0 Toxicité @5 18`
C03	`14`	`X`	`ENG`	`@0 Toxicity @5 18`
C03	`14`	`X`	`SPA`	`@0 Toxicidad @5 18`
C03	`15`	`X`	`FRE`	`@0 Homme @5 20`
C03	`15`	`X`	`ENG`	`@0 Human @5 20`
C03	`15`	`X`	`SPA`	`@0 Hombre @5 20`
C03	`16`	`X`	`FRE`	`@0 Court terme @5 23`
C03	`16`	`X`	`ENG`	`@0 Short term @5 23`
C03	`16`	`X`	`SPA`	`@0 Corto plazo @5 23`
C07	`01`	`X`	`FRE`	`@0 Système nerveux pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Nervous system diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema nervioso patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Central nervous system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Encéphale pathologie @5 39`
C07	`03`	`X`	`ENG`	`@0 Cerebral disorder @5 39`
C07	`03`	`X`	`SPA`	`@0 Encéfalo patología @5 39`
C07	`04`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 40`
C07	`04`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 40`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 41`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 41`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 41`
N21				`@1 008`

Format Inist (serveur)

NO :	PASCAL 01-0017681 INIST
ET :	Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
AU :	MOHR (Erich); MENDIS (Tilak); HILDEBRAND (Kathleen); DE DEYN (Peter Paul)
AF :	CroMedica Global Inc./Victoria/Canada (1 aut., 3 aut.); University of Ottawa/Canada (1 aut., 3 aut.); Ottawa Civic Hospital and University of Ottawa/Canada (2 aut.); Middelheim Hospital, University of Antwerp/Antwerp/Belgique (4 aut.)
DT :	Publication en série; Courte communication, note brève; Niveau analytique
SO :	Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 6; Pp. 1230-1237; Bibl. 50 ref.
LA :	Anglais
EA :	PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (-3.1 decrease) after 1 week and a 66% improvement (-6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)-severity and CGI-improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short-term use of risperidone (mean dosage, 1, 1 mg per day) improves the psychopathology of patients with PD who have dopamine-induced psychosis without adversely affecting the symptoms of PD. Higher doses and long-term use were not addressed in this study and may be precluded by extrapyramidal side effects.
CC :	002B02U01
FD :	Parkinson maladie; Psychose; Lévodopa; Chimiothérapie; Antiparkinsonien; Rispéridone; Neuroleptique; Psychotrope; Antagoniste dopamine; Antagoniste sérotonine; Récepteur dopaminergique; Récepteur sérotoninergique; Traitement; Toxicité; Homme; Court terme
FG :	Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative
ED :	Parkinson disease; Psychosis; Levodopa; Chemotherapy; Antiparkinson agent; Risperidone; Neuroleptic; Psychotropic; Dopamine antagonist; Serotonin antagonist; Dopamine receptor; Serotonine receptor; Treatment; Toxicity; Human; Short term
EG :	Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease
SD :	Parkinson enfermedad; Psicosis; Levodopa; Quimioterapia; Antiparkinsoniano; Risperidona; Neuroléptico; Psicotropo; Antagonista dopamina; Antagonista serotonina; Receptor dopaminérgico; Receptor serotoninérgico; Tratamiento; Toxicidad; Hombre; Corto plazo
LO :	INIST-20953.354000092814950260
ID :	01-0017681

Links to Exploration step

Pascal:01-0017681

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial</title>
<author><name sortKey="Mohr, Erich" sort="Mohr, Erich" uniqKey="Mohr E" first="Erich" last="Mohr">Erich Mohr</name>
<affiliation><inist:fA14 i1="01"><s1>CroMedica Global Inc.</s1>
<s2>Victoria</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Ottawa</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mendis, Tilak" sort="Mendis, Tilak" uniqKey="Mendis T" first="Tilak" last="Mendis">Tilak Mendis</name>
<affiliation><inist:fA14 i1="03"><s1>Ottawa Civic Hospital and University of Ottawa</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hildebrand, Kathleen" sort="Hildebrand, Kathleen" uniqKey="Hildebrand K" first="Kathleen" last="Hildebrand">Kathleen Hildebrand</name>
<affiliation><inist:fA14 i1="01"><s1>CroMedica Global Inc.</s1>
<s2>Victoria</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Ottawa</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name>
<affiliation><inist:fA14 i1="04"><s1>Middelheim Hospital, University of Antwerp</s1>
<s2>Antwerp</s2>
<s3>BEL</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">01-0017681</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 01-0017681 INIST</idno>
<idno type="RBID">Pascal:01-0017681</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C56</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial</title>
<author><name sortKey="Mohr, Erich" sort="Mohr, Erich" uniqKey="Mohr E" first="Erich" last="Mohr">Erich Mohr</name>
<affiliation><inist:fA14 i1="01"><s1>CroMedica Global Inc.</s1>
<s2>Victoria</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Ottawa</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mendis, Tilak" sort="Mendis, Tilak" uniqKey="Mendis T" first="Tilak" last="Mendis">Tilak Mendis</name>
<affiliation><inist:fA14 i1="03"><s1>Ottawa Civic Hospital and University of Ottawa</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Hildebrand, Kathleen" sort="Hildebrand, Kathleen" uniqKey="Hildebrand K" first="Kathleen" last="Hildebrand">Kathleen Hildebrand</name>
<affiliation><inist:fA14 i1="01"><s1>CroMedica Global Inc.</s1>
<s2>Victoria</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>University of Ottawa</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="De Deyn, Peter Paul" sort="De Deyn, Peter Paul" uniqKey="De Deyn P" first="Peter Paul" last="De Deyn">Peter Paul De Deyn</name>
<affiliation><inist:fA14 i1="04"><s1>Middelheim Hospital, University of Antwerp</s1>
<s2>Antwerp</s2>
<s3>BEL</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson agent</term>
<term>Chemotherapy</term>
<term>Dopamine antagonist</term>
<term>Dopamine receptor</term>
<term>Human</term>
<term>Levodopa</term>
<term>Neuroleptic</term>
<term>Parkinson disease</term>
<term>Psychosis</term>
<term>Psychotropic</term>
<term>Risperidone</term>
<term>Serotonin antagonist</term>
<term>Serotonine receptor</term>
<term>Short term</term>
<term>Toxicity</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term>
<term>Psychose</term>
<term>Lévodopa</term>
<term>Chimiothérapie</term>
<term>Antiparkinsonien</term>
<term>Rispéridone</term>
<term>Neuroleptique</term>
<term>Psychotrope</term>
<term>Antagoniste dopamine</term>
<term>Antagoniste sérotonine</term>
<term>Récepteur dopaminergique</term>
<term>Récepteur sérotoninergique</term>
<term>Traitement</term>
<term>Toxicité</term>
<term>Homme</term>
<term>Court terme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (-3.1 decrease) after 1 week and a 66% improvement (-6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)-severity and CGI-improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short-term use of risperidone (mean dosage, 1, 1 mg per day) improves the psychopathology of patients with PD who have dopamine-induced psychosis without adversely affecting the symptoms of PD. Higher doses and long-term use were not addressed in this study and may be precluded by extrapyramidal side effects.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>6</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MOHR (Erich)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MENDIS (Tilak)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HILDEBRAND (Kathleen)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DE DEYN (Peter Paul)</s1>
</fA11>
<fA14 i1="01"><s1>CroMedica Global Inc.</s1>
<s2>Victoria</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>University of Ottawa</s1>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Ottawa Civic Hospital and University of Ottawa</s1>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Middelheim Hospital, University of Antwerp</s1>
<s2>Antwerp</s2>
<s3>BEL</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA20><s1>1230-1237</s1>
</fA20>
<fA21><s1>2000</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000092814950260</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2001 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>50 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>01-0017681</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (-3.1 decrease) after 1 week and a 66% improvement (-6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)-severity and CGI-improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short-term use of risperidone (mean dosage, 1, 1 mg per day) improves the psychopathology of patients with PD who have dopamine-induced psychosis without adversely affecting the symptoms of PD. Higher doses and long-term use were not addressed in this study and may be precluded by extrapyramidal side effects.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Psychose</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Psychosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Psicosis</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Lévodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Levodopa</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Rispéridone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Risperidone</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Risperidona</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Neuroleptique</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Neuroleptic</s0>
<s5>11</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Neuroléptico</s0>
<s5>11</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Psychotrope</s0>
<s2>FX</s2>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Psychotropic</s0>
<s2>FX</s2>
<s5>12</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Psicotropo</s0>
<s2>FX</s2>
<s5>12</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Antagoniste dopamine</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Dopamine antagonist</s0>
<s5>13</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Antagonista dopamina</s0>
<s5>13</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Antagoniste sérotonine</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Serotonin antagonist</s0>
<s5>14</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Antagonista serotonina</s0>
<s5>14</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Récepteur dopaminergique</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Dopamine receptor</s0>
<s5>15</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Receptor dopaminérgico</s0>
<s5>15</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Récepteur sérotoninergique</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Serotonine receptor</s0>
<s5>16</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Receptor serotoninérgico</s0>
<s5>16</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Traitement</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Treatment</s0>
<s5>17</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>17</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Toxicité</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Toxicity</s0>
<s5>18</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Toxicidad</s0>
<s5>18</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Court terme</s0>
<s5>23</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Short term</s0>
<s5>23</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Corto plazo</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>41</s5>
</fC07>
<fN21><s1>008</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 01-0017681 INIST</NO>
<ET>Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial</ET>
<AU>MOHR (Erich); MENDIS (Tilak); HILDEBRAND (Kathleen); DE DEYN (Peter Paul)</AU>
<AF>CroMedica Global Inc./Victoria/Canada (1 aut., 3 aut.); University of Ottawa/Canada (1 aut., 3 aut.); Ottawa Civic Hospital and University of Ottawa/Canada (2 aut.); Middelheim Hospital, University of Antwerp/Antwerp/Belgique (4 aut.)</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 2000; Vol. 15; No. 6; Pp. 1230-1237; Bibl. 50 ref.</SO>
<LA>Anglais</LA>
<EA>PURPOSE: To evaluate the safety and efficacy of risperidone in patients with Parkinson's disease (PD) who are experiencing significant dopamine-induced psychosis. PATIENTS AND METHODS: Seventeen patients (median age, 72 yrs) participated in this 12-week, open pilot study receiving 0.5 to 3 mg oral risperidone per day. Maintenance antiparkinsonian medication was continued throughout, although psychotropic medication was discontinued. EFFICACY RESULTS: Risperidone produced a substantial improvement in psychotic symptoms, shown on the mean total positive subscale score on the Positive and Negative Syndrome Scale (PANSS) by a 30% improvement (-3.1 decrease) after 1 week and a 66% improvement (-6.8 decrease) at end point. This improvement was most evident in the items delusions, hallucinatory behavior, and suspiciousness/persecution. Risperidone also achieved significant improvement from baseline in Clinical Global Impression (CGI)-severity and CGI-improvement (p <0.001, Page test). Risperidone treatment did not adversely affect symptoms specific to Parkinson's disease, as assessed by the Unified Parkinson's Disease Rating Scale (UPDRS). SAFETY RESULTS: Sixteen patients reported at least one adverse event, but only two patients withdrew as a result of adverse events. No significant changes or clinically relevant abnormalities were observed in laboratory parameters or vital signs. CONCLUSION: Short-term use of risperidone (mean dosage, 1, 1 mg per day) improves the psychopathology of patients with PD who have dopamine-induced psychosis without adversely affecting the symptoms of PD. Higher doses and long-term use were not addressed in this study and may be precluded by extrapyramidal side effects.</EA>
<CC>002B02U01</CC>
<FD>Parkinson maladie; Psychose; Lévodopa; Chimiothérapie; Antiparkinsonien; Rispéridone; Neuroleptique; Psychotrope; Antagoniste dopamine; Antagoniste sérotonine; Récepteur dopaminergique; Récepteur sérotoninergique; Traitement; Toxicité; Homme; Court terme</FD>
<FG>Système nerveux pathologie; Système nerveux central pathologie; Encéphale pathologie; Extrapyramidal syndrome; Maladie dégénérative</FG>
<ED>Parkinson disease; Psychosis; Levodopa; Chemotherapy; Antiparkinson agent; Risperidone; Neuroleptic; Psychotropic; Dopamine antagonist; Serotonin antagonist; Dopamine receptor; Serotonine receptor; Treatment; Toxicity; Human; Short term</ED>
<EG>Nervous system diseases; Central nervous system disease; Cerebral disorder; Extrapyramidal syndrome; Degenerative disease</EG>
<SD>Parkinson enfermedad; Psicosis; Levodopa; Quimioterapia; Antiparkinsoniano; Risperidona; Neuroléptico; Psicotropo; Antagonista dopamina; Antagonista serotonina; Receptor dopaminérgico; Receptor serotoninérgico; Tratamiento; Toxicidad; Hombre; Corto plazo</SD>
<LO>INIST-20953.354000092814950260</LO>
<ID>01-0017681</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C56 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000C56 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:01-0017681
   |texte=   Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri